Iodinated contrast agents
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypothyroidism
Conditions
Hypothyroidism
Trial Timeline
Oct 15, 2016 → Jun 15, 2017
NCT ID
NCT02959827About Iodinated contrast agents
Iodinated contrast agents is a pre-clinical stage product being developed by Bayer for Hypothyroidism. The current trial status is completed. This product is registered under clinical trial identifier NCT02959827. Target conditions include Hypothyroidism.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02959827 | Pre-clinical | Completed |
| NCT02766283 | Pre-clinical | Completed |
Competing Products
5 competing products in Hypothyroidism
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Growth hormone + Growth hormone treatment and puberty | Eli Lilly | Approved | 85 |
| Armour Thyroid + Levothyroxine | AbbVie | Phase 2/3 | 65 |
| iodinated contrast agents | Bayer | Pre-clinical | 20 |
| Iohexol + Iodixanol + Iopromide + Ioversol | Bayer | Approved | 82 |
| levothyroxine sodium | Xeris Pharmaceuticals | Phase 2 | 47 |